Featured Articles

1. Godzilla Vs. The Life Sciences Supply Chain 7/8/2026

   A “Godzilla” El Niño could disrupt pharma supply chains, pushing life sciences firms toward AI-driven weather forecasting, scenario planning, and climate resilience.

2. BIO 2026: China, AI, And FDA 7/6/2026

   What happened at BIO? This selected coverage from the BIO 2026 meeting in San Francisco includes highlights from panels on China, AI, and an FDA Town Hall.

3. Beyond The Fine Print: OPDP's 2026 DTC Letters Redefine Net Impression 6/29/2026

   FDA’s OPDP untitled letters show rising scrutiny of DTC ads’ overall impression on consumers and urge companies to balance benefit claims with clear product risks.

4. The Next Chapter Of Obesity And Type 2 Diabetes Care: ADA 2026 Signals A More Personalized Future 6/23/2026

   The American Diabetes Association 2026 conference showed where we are and where we're going with GLP-1 therapies.

5. Understanding FDA's Plausible Mechanism Framework For Genetic Medicines 6/19/2026

   FDA’s draft “plausible mechanism” framework gives individualized genetic therapies a clearer path to market, but questions remain, write experts at Morrison Foerster.

6. Future Patients: Why Procurement Matters In Emerging Life Sciences 6/16/2026

   As emerging biotechs scale, procurement is becoming a key lever for patient access, resilience, and long-term commercial success.

7. The Fatal Flaw In Pharma's Multi-Million Supply Chain Tech Upgrades 6/12/2026

   AI tools improve visibility, but pharma supply chains stay fragile when leaders favor cost and efficiency over diversification, redundancy, and long-term resilience.

8. From Clinical To Market: Managing Pharma's Most Challenging Transition 6/10/2026

   For drugmakers, approval is just the opening bell; the challenge is turning scientific success into commercial traction, writes ARS Pharmaceutical CEO Richard Lowenthal.

9. How Small And Midsize Pharma Companies Can Fight Drug Diversion 6/8/2026

   Illegal online pharmacies cost biopharma billions and put lives at risk. Small and midsize companies must move fast to safeguard patients and protect product integrity.

10. Five Ways To Unleash The Potential Of Women In STEM 6/5/2026

    Women earn STEM degrees at high rates but remain underrepresented in STEM jobs and leadership. A biotech exec outlines five ways to close the gap.